Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Blog|Videos|June 7, 2023
The Good Burnout News About Medical Marriages
Author(s)H. Steven Moffic, MD
Married to the job...? No more.
Advertisement
Psychiatry & Society
H. Steven Moffic, MD, discusses medical marriages. How have medical marriages changed since the pandemic? Dr Moffic recommends you watch Richard Berlin, MD's poem, "
Dr Moffic is an award-winning psychiatrist who has specialized in the cultural and ethical aspects of psychiatry. A prolific writer and speaker, he received the one-time designation of Hero of Public Psychiatry from the Assembly of the American Psychiatric Association in 2002. He is an advocate for mental health issues related to climate instability, burnout, Islamophobia, and anti-Semitism for a better world. He serves on the Editorial Board of Psychiatric Times.
Advertisement
Related to this article
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Spot SVT or POTS masquerading as panic attacks—key heart-rate clues, home maneuvers, and why anxiety can persist even after arrhythmia treatment.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
In this case exploration, a teen survives a gun injury yet denies self-harm, pushing clinicians to read beyond words and plan safety when suicide intent is unclear.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
Brenipatide for Alcohol Use Disorder: Emerging Findings
3
New Real-World Data Supporting Cariprazine for MDD and Bipolar I Depression
4
New Adult ADHD Guidelines: What Resources Are Coming Soon
5